521 related articles for article (PubMed ID: 25486992)
21. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.
Davies NL; Compson JE; Mackenzie B; O'Dowd VL; Oxbrow AK; Heads JT; Turner A; Sarkar K; Dugdale SL; Jairaj M; Christodoulou L; Knight DE; Cross AS; Hervé KJ; Tyson KL; Hailu H; Doyle CB; Ellis M; Kriek M; Cox M; Page MJ; Moore AR; Lightwood DJ; Humphreys DP
Clin Vaccine Immunol; 2013 Mar; 20(3):377-90. PubMed ID: 23324518
[TBL] [Abstract][Full Text] [Related]
22. Recombinant lipoprotein-based vaccine candidates against C. difficile infections.
Huang JH; Wu CW; Lien SP; Leng CH; Hsiao KN; Liu SJ; Chen HW; Siu LK; Chong P
J Biomed Sci; 2015 Aug; 22(1):65. PubMed ID: 26245825
[TBL] [Abstract][Full Text] [Related]
23. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
[TBL] [Abstract][Full Text] [Related]
24. A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection.
Schmidt DJ; Beamer G; Tremblay JM; Steele JA; Kim HB; Wang Y; Debatis M; Sun X; Kashentseva EA; Dmitriev IP; Curiel DT; Shoemaker CB; Tzipori S
Clin Vaccine Immunol; 2016 Sep; 23(9):774-84. PubMed ID: 27413067
[TBL] [Abstract][Full Text] [Related]
25. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.
Yang Z; Schmidt D; Liu W; Li S; Shi L; Sheng J; Chen K; Yu H; Tremblay JM; Chen X; Piepenbrink KH; Sundberg EJ; Kelly CP; Bai G; Shoemaker CB; Feng H
J Infect Dis; 2014 Sep; 210(6):964-72. PubMed ID: 24683195
[TBL] [Abstract][Full Text] [Related]
26. Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.
Kufel WD; Devanathan AS; Marx AH; Weber DJ; Daniels LM
Pharmacotherapy; 2017 Oct; 37(10):1298-1308. PubMed ID: 28730660
[TBL] [Abstract][Full Text] [Related]
27. Oral Immunization with Nontoxigenic Clostridium difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against C. difficile Infection in Both Mice and Hamsters.
Wang Y; Wang S; Bouillaut L; Li C; Duan Z; Zhang K; Ju X; Tzipori S; Sonenshein AL; Sun X
Infect Immun; 2018 Nov; 86(11):. PubMed ID: 30150259
[TBL] [Abstract][Full Text] [Related]
28. Memory B Cells Encode Neutralizing Antibody Specific for Toxin B from the Clostridium difficile Strains VPI 10463 and NAP1/BI/027 but with Superior Neutralization of VPI 10463 Toxin B.
Devera TS; Lang GA; Lanis JM; Rampuria P; Gilmore CL; James JA; Ballard JD; Lang ML
Infect Immun; 2016 Jan; 84(1):194-204. PubMed ID: 26502913
[TBL] [Abstract][Full Text] [Related]
29. Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection.
Yang Z; Shi L; Yu H; Zhang Y; Chen K; Saint Fleur A; Bai G; Feng H
Pathog Dis; 2016 Oct; 74(7):. PubMed ID: 27502696
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography.
Orth P; Xiao L; Hernandez LD; Reichert P; Sheth PR; Beaumont M; Yang X; Murgolo N; Ermakov G; DiNunzio E; Racine F; Karczewski J; Secore S; Ingram RN; Mayhood T; Strickland C; Therien AG
J Biol Chem; 2014 Jun; 289(26):18008-21. PubMed ID: 24821719
[TBL] [Abstract][Full Text] [Related]
31. The roles of toxin A and toxin B in Clostridium difficile infection: insights from the gnotobiotic piglet model.
Steele J; Parry N; Tzipori S
Gut Microbes; 2014; 5(1):53-7. PubMed ID: 24394234
[TBL] [Abstract][Full Text] [Related]
32. Mouse relapse model of Clostridium difficile infection.
Sun X; Wang H; Zhang Y; Chen K; Davis B; Feng H
Infect Immun; 2011 Jul; 79(7):2856-64. PubMed ID: 21576341
[TBL] [Abstract][Full Text] [Related]
33. Treatment with monoclonal antibodies against Clostridium difficile toxins.
Lowy I; Molrine DC; Leav BA; Blair BM; Baxter R; Gerding DN; Nichol G; Thomas WD; Leney M; Sloan S; Hay CA; Ambrosino DM
N Engl J Med; 2010 Jan; 362(3):197-205. PubMed ID: 20089970
[TBL] [Abstract][Full Text] [Related]
34. Deciphering the domain specificity of C. difficile toxin neutralizing antibodies.
Cole LE; Li L; Jetley U; Zhang J; Pacheco K; Ma F; Zhang J; Mundle S; Yan Y; Barone L; Rogers C; Beltraminelli N; Quemeneur L; Kleanthous H; Anderson SF; Anosova NG
Vaccine; 2019 Jun; 37(29):3892-3901. PubMed ID: 31122858
[TBL] [Abstract][Full Text] [Related]
35. The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients.
Mikamo H; Aoyama N; Sawata M; Fujimoto G; Dorr MB; Yoshinari T
J Infect Chemother; 2018 Feb; 24(2):123-129. PubMed ID: 29097028
[TBL] [Abstract][Full Text] [Related]
36. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters.
Giannasca PJ; Zhang ZX; Lei WD; Boden JA; Giel MA; Monath TP; Thomas WD
Infect Immun; 1999 Feb; 67(2):527-38. PubMed ID: 9916055
[TBL] [Abstract][Full Text] [Related]
37. Identification of toxemia in patients with Clostridium difficile infection.
Yu H; Chen K; Wu J; Yang Z; Shi L; Barlow LL; Aronoff DM; Garey KW; Savidge TC; von Rosenvinge EC; Kelly CP; Feng H
PLoS One; 2015; 10(4):e0124235. PubMed ID: 25885671
[TBL] [Abstract][Full Text] [Related]
38. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
Wilcox MH; Gerding DN; Poxton IR; Kelly C; Nathan R; Birch T; Cornely OA; Rahav G; Bouza E; Lee C; Jenkin G; Jensen W; Kim YS; Yoshida J; Gabryelski L; Pedley A; Eves K; Tipping R; Guris D; Kartsonis N; Dorr MB;
N Engl J Med; 2017 Jan; 376(4):305-317. PubMed ID: 28121498
[TBL] [Abstract][Full Text] [Related]
39. The Murine Neonatal Fc Receptor Is Required for Transport of Immunization-Induced C. difficile-Specific IgG to the Gut and Protection against Disease but Does Not Affect Disease Susceptibility.
Amadou Amani S; Lang GA; Ballard JD; Lang ML
Infect Immun; 2021 Sep; 89(10):e0027421. PubMed ID: 34097471
[TBL] [Abstract][Full Text] [Related]
40. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.
Tian JH; Fuhrmann SR; Kluepfel-Stahl S; Carman RJ; Ellingsworth L; Flyer DC
Vaccine; 2012 Jun; 30(28):4249-58. PubMed ID: 22537987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
